Tapewire

Nasdaq · USD

OPK

OPKO HEALTH, INC.

Export transactions ↓
Tapewire entity
4891
SEC CIK
0000944809
Parsed reports
659

Last 12 months

Inside the activity.

33 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025320
Dec 202500
Jan 202600
Feb 202600
Mar 202610
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 16, 2022 Filed May 17, 2022 10:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,300 $2.97 $9,784.50
Disclosure

SEC source: 0001209191-22-029463 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,778,936

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 16, 2022 Filed May 17, 2022 10:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 18,282 $2.96 $54,114.72
Disclosure

SEC source: 0001209191-22-029463 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,775,636

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 16, 2022 Filed May 17, 2022 10:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 660 $2.96 $1,950.30
Disclosure

SEC source: 0001209191-22-029463 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,757,354

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400 $3.04 $1,216.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 20

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,756,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 6,000 $3.04 $18,210.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 19

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,756,294

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 13,200 $3.03 $39,996.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 18

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,750,294

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 14,023 $3.03 $42,419.58
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 17

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,737,094

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 12,700 $3.02 $38,354.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 16

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,723,071

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,577 $3.02 $10,784.66
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 15

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,710,371

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 19,902 $3.01 $59,905.02
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 14

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,706,794

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 7,223 $3.01 $21,705.12
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 13

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,686,892

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 7,370 $3.00 $22,110.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 12

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,679,669

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 11,630 $3.00 $34,831.85
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 11

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,672,299

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 27,600 $2.99 $82,524.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 10

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,660,669

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 12,975 $2.99 $38,730.38
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 9

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,633,069

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 31,420 $2.98 $93,631.60
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,620,094

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 17,080 $2.98 $50,813.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,588,674

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 600 $2.97 $1,782.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,571,594

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 900 $2.97 $2,668.50
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,570,994

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 8,500 $2.96 $25,160.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,570,094

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,800 $2.96 $11,229.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,561,594

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2022 Filed May 16, 2022 11:17 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 1,100 $2.95 $3,245.00
Disclosure

SEC source: 0001209191-22-029018 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,557,794

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 12, 2022 Filed May 19, 2022 20:28 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 6,979 $2.65 $18,494.35
Disclosure

SEC source: 0001209191-22-030517 · doc4.xml · nonDerivative · entry 1

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,979

Read SEC document
May 11, 2022 Filed May 12, 2022 10:50 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400,000 $2.83 $1,132,400.00
Disclosure

SEC source: 0001209191-22-028441 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,556,694

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.68 to $2.985, inclusive. The reporting person undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 10, 2022 Filed May 11, 2022 10:49 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400,000 $2.78 $1,113,560.00
Disclosure

SEC source: 0001209191-22-028189 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 195,156,694

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.605 to $2.965, inclusive. The reporting person undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 10, 2022 Filed May 12, 2022 01:01 UTC
Zerhouni Elias A.Director · Vice Chairman and President
PurchaseCommon Stock 89,600 $2.79 $250,396.16
Disclosure

SEC source: 0001209191-22-028425 · doc4.xml · nonDerivative · entry 1

Zerhouni Elias A. · CIK 0001478398 · Director · Vice Chairman and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,600

Read SEC document
May 09, 2022 Filed May 12, 2022 01:44 UTC
Nabel Gary J.Director · Chief Innovation Officer
GrantStock Option (Right to Buy) · Derivative 34,923 $0.00 Strike: $3.20 $0.00
Disclosure

SEC source: 0001209191-22-028435 · doc4.xml · derivative · entry 1

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,923

Underlying: Common Stock · 34,923 shares

Expires 2032-05-08

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 9, 2023.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:01 UTC
Zerhouni Elias A.Director · Vice Chairman and President
GrantStock Option (Right to Buy) · Derivative 34,923 $0.00 Strike: $3.20 $0.00
Disclosure

SEC source: 0001209191-22-028425 · doc4.xml · derivative · entry 2

Zerhouni Elias A. · CIK 0001478398 · Director · Vice Chairman and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,923

Underlying: Common Stock · 34,923 shares

Expires 2032-05-08

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 9, 2023.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:00 UTC GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $2.44 $0.00
Disclosure

SEC source: 0001209191-22-028424 · doc4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-05-08

Read SEC document
May 09, 2022 Filed May 12, 2022 01:00 UTC GrantCommon Stock 312,612 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-028424 · doc4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,612

F1 · shares: On May 9, 2022, the Issuer awarded the Reporting Person restricted stock in the amount indicated. The restricted stock vests in four equal installments, beginning on May 9, 2023.

Read SEC document
May 09, 2022 Filed May 13, 2022 22:19 UTC Amendment GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $2.44 $0.00
Disclosure

SEC source: 0001209191-22-028956 · doc4a.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-05-08

Read SEC document
May 09, 2022 Filed May 13, 2022 22:19 UTC Amendment GrantCommon Stock 312,612 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-028956 · doc4a.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,612

F1 · shares: On May 9, 2022, the Issuer awarded the Reporting Person restricted stock in the amount indicated in connection with the merger between the Issuer and ModeX Therapeutics, Inc. ("ModeX"), pursuant to which ModeX became a subsidiary of the Issuer.

Read SEC document
May 09, 2022 Filed Jun 22, 2022 20:42 UTC Amendment
Zerhouni Elias A.Director · Vice Chairman and President
GrantCommon Stock 19,777,514 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-038693 · doc4a.xml · nonDerivative · entry 2

Zerhouni Elias A. · CIK 0001478398 · Director · Vice Chairman and President

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the EAZ ZERAZ TRUST

Disclosed balance after: 19,777,514

F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the ZERHOUNI IRREVOCABLE TRUST and the EAZ ZERAZ TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4.

F4 · price: Received in exchange for 2,250,000 shares of ModeX held directly by the EAZ ZERAZ TRUST in connection with the ModeX Merger.

F5 · ownership.nature: Shares held by the EAZ ZERAZ TRUST for the benefit of the Reporting Person's spouse and children and remoter issue, as well as certain qualifying charitable organizations, and for which an independent trustee has been appointed. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 09, 2022 Filed Jun 22, 2022 20:42 UTC Amendment
Zerhouni Elias A.Director · Vice Chairman and President
GrantCommon Stock 19,777,514 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-038693 · doc4a.xml · nonDerivative · entry 1

Zerhouni Elias A. · CIK 0001478398 · Director · Vice Chairman and President

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the ZERHOUNI IRREVOCABLE TRUST

Disclosed balance after: 19,777,514

F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the ZERHOUNI IRREVOCABLE TRUST and the EAZ ZERAZ TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4.

F2 · price: Received in exchange for 2,250,000 shares of ModeX Therapeutics, Inc., a Delaware corporation ("ModeX"), held directly by the ZERHOUNI IRREVOCABLE TRUST in connection with the Agreement and Plan of Merger, dated as of May 9, 2022, by and among the Issuer, ModeX, Orca Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer, and Gary J. Nabel, solely in his capacity as sellers' representative, pursuant to which ModeX became a wholly owned subsidiary of the Issuer (the "ModeX Merger").

F3 · ownership.nature: Shares held by the ZERHOUNI IRREVOCABLE TRUST for the benefit of the Reporting Person and his children and remoter issue, as well as certain qualifying charitable organizations, and for which an independent trustee has been appointed. The independent trustee has delegated investment authority of the trust to the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 09, 2022 Filed Jun 22, 2022 20:45 UTC Amendment
Nabel Gary J.Director · Chief Innovation Officer
GrantCommon Stock 19,777,514 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-038694 · doc4a.xml · nonDerivative · entry 2

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the EGN 2021 TRUST

Disclosed balance after: 19,777,514

F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the GJN 2021 TRUST and the EGN 2021 TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4.

F4 · price: Received in exchange for 2,250,000 shares of ModeX held directly by the EGN 2021 TRUST in connection with the ModeX Merger.

F5 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 09, 2022 Filed Jun 22, 2022 20:45 UTC Amendment
Nabel Gary J.Director · Chief Innovation Officer
GrantCommon Stock 19,777,514 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-038694 · doc4a.xml · nonDerivative · entry 1

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the GJN 2021 TRUST

Disclosed balance after: 19,777,514

F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the GJN 2021 TRUST and the EGN 2021 TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4.

F2 · price: Received in exchange for 2,250,000 shares of ModeX Therapeutics, Inc., a Delaware corporation ("ModeX"), held directly by the GJN 2021 TRUST in connection with the Agreement and Plan of Merger, dated as of May 9, 2022, by and among the Issuer, ModeX, Orca Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer, and Gary J. Nabel, solely in his capacity as sellers' representative, pursuant to which ModeX became a wholly owned subsidiary of the Issuer (the "ModeX Merger").

F3 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 11:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 15,845 $3.05 $48,327.25
Disclosure

SEC source: 0001209191-22-018683 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,756,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 11:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,200 $3.03 $27,876.00
Disclosure

SEC source: 0001209191-22-018683 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,740,849

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 11:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,955 $3.03 $30,113.88
Disclosure

SEC source: 0001209191-22-018683 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,731,649

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 11:16 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 73,037 $3.13 $228,605.81
Disclosure

SEC source: 0001209191-22-018347 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,721,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 11:16 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 26,863 $3.13 $83,946.88
Disclosure

SEC source: 0001209191-22-018347 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,648,657

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 11:16 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 100 $3.12 $312.00
Disclosure

SEC source: 0001209191-22-018347 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,621,794

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 10,000 $3.13 $31,250.00
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 9

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,621,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 10,000 $3.12 $31,200.00
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,611,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 15,000 $3.12 $46,725.00
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,601,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 49,205 $3.11 $152,781.53
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,586,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 420 $3.10 $1,302.00
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,537,489

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 10,375 $3.10 $32,110.63
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,537,069

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 300 $3.09 $927.00
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,526,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
February 28, 2022 Filed Mar 1, 2022 12:33 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 4,700 $3.09 $14,499.50
Disclosure

SEC source: 0001209191-22-013836 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 194,526,394

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.